Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion.

Although dysregulation of bone morphogenetic protein (BMP) signaling has been linked to various types of cancers, the relationship between abnormal activation of these signaling pathways and tumorigenesis is not clear. The purpose of the current study was to clarify how BMP2 is involved in colon cancer aggressiveness. The data showed that SW480 and DLD-1 cells displayed different responses to short- and long-term exposure to BMP2. During the first 24 h of exposure to BMP2, these cells were growth-inhibited, whereas surviving cells became resistant to growth inhibition, showing epithelial-to-mesenchymal transformation (EMT) and enhanced motility and invasiveness. Interestingly, in highly metastatic mesenchymal colon carcinoma cells (CT26), blockade of BMP2 signaling by BMP2 siRNA prevented EMT, motility and invasiveness; rather, blockade of BMP2 signaling caused a mesenchymal-to-epithelial transition (MET). The levels of phosphorylated Akt were very different between the two cell types; the BMP2-sensitive SW480 and DLD-1 cells had much higher levels of expression than the BMP2-resistant SW480 and DLD-1 and CT26 cells. CT26 cells, following exposure to BMP2 and activation of Akt, escaped the EMT-induced cellular motility and invasiveness. Moreover, LY294002 treatment of BMP2-sensitive SW480 cells blocked cell growth and enhanced motility and invasiveness. Together, these results suggest that suppression of the PI3 kinase/Akt pathway is correlated with the development of BMP2 resistance and invasion in BMP2-induced EMT in colon cancer.

[1]  C. Tepper,et al.  Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. , 2008, Cancer research.

[2]  J. Carethers,et al.  BMP suppresses PTEN expression via RAS/ERK signaling , 2007, Cancer biology & therapy.

[3]  M. Nachtigal,et al.  BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. , 2007, Carcinogenesis.

[4]  T. Mustelin,et al.  Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-β II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN , 2007, Leukemia & lymphoma.

[5]  E. Langenfeld,et al.  Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5 , 2006, Oncogene.

[6]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[7]  E. Langenfeld,et al.  Bone Morphogenetic Protein-2–Induced Transformation Involves the Activation of Mammalian Target of Rapamycin , 2005, Molecular Cancer Research.

[8]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[9]  E. Langenfeld,et al.  Expression of bone morphogenetic proteins in human lung carcinomas. , 2005, The Annals of thoracic surgery.

[10]  Di Chen,et al.  The BMP signaling and in vivo bone formation. , 2005, Gene.

[11]  L. Harrison,et al.  Convergence of bone morphogenetic protein and laminin-1 signaling pathways promotes proliferation and colony formation by fetal mouse pancreatic cells. , 2005, Experimental cell research.

[12]  A. Mercurio,et al.  The epithelial-mesenchymal tansition (EMT) and colorectal cancer progression , 2005, Cancer biology & therapy.

[13]  A. Bosserhoff,et al.  Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. , 2005, Cancer research.

[14]  Haiyan Wu,et al.  The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch. , 2004, Archives of biochemistry and biophysics.

[15]  Di Chen,et al.  Bone Morphogenetic Proteins , 2004, Growth factors.

[16]  F. E. Bertrand,et al.  The complexity of PTEN: mutation, marker and potential target for therapeutic intervention , 2004, Expert opinion on therapeutic targets.

[17]  Seong-Jin Kim,et al.  Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells , 2004, Oncogene.

[18]  Ossama Tawfik,et al.  BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt–β-catenin signaling , 2004, Nature Genetics.

[19]  J. Martín-Pérez,et al.  Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions , 2004, Oncogene.

[20]  Hans Clevers,et al.  De Novo Crypt Formation and Juvenile Polyposis on BMP Inhibition in Mouse Intestine , 2004, Science.

[21]  E. Langenfeld,et al.  Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. , 2004, Molecular cancer research : MCR.

[22]  S. Calvano,et al.  The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. , 2003, Carcinogenesis.

[23]  J. Keller,et al.  Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. , 2003, Gastroenterology.

[24]  C. Eng,et al.  BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. , 2003, Human molecular genetics.

[25]  P. Pelicci,et al.  Tumour-associated hypermethylation: silencing E-cadherin expression enhances invasion and metastasis. , 2003, European journal of cancer.

[26]  L. Aaltonen,et al.  PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. , 2002, The American journal of pathology.

[27]  M. Tachibana,et al.  Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma , 2002, Cancer.

[28]  K. Miyazono,et al.  Divergence and convergence of TGF‐β/BMP signaling , 2001, Journal of cellular physiology.

[29]  G. Tipoe,et al.  Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. , 2001, Oral oncology.

[30]  P Komminoth,et al.  Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. , 2000, The American journal of pathology.

[31]  S. F. Arnold,et al.  Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2. , 1999, Cytokine.

[32]  F. Hamdy,et al.  Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. , 1997, Cancer research.

[33]  J. Wozney,et al.  The bone morphogenetic protein family and osteogenesis , 1992, Molecular reproduction and development.

[34]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988, Science.

[35]  M. Brattain,et al.  Establishment of mouse colonic carcinoma cell lines with different metastatic properties. , 1980, Cancer research.

[36]  Brian Bierie,et al.  TGF-beta and cancer. , 2006, Cytokine & growth factor reviews.

[37]  I. Kitajima,et al.  BMP-2 prevents apoptosis of the N1511 chondrocytic cell line through PI3K/Akt-mediated NF-κB activation , 2005, Journal of Bone and Mineral Metabolism.

[38]  Baljit Singh,et al.  Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. , 2002, Cancer research.

[39]  R. Derynck,et al.  Smads: transcriptional activators of TGF-beta responses. , 1998, Cell.